Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 01 2020
Historique:
received: 06 08 2019
revised: 19 08 2019
accepted: 28 08 2019
pubmed: 11 9 2019
medline: 4 3 2021
entrez: 11 9 2019
Statut: ppublish

Résumé

Over the last decades, the profile of chronic coronary syndrome has changed substantially. We aimed to determine characteristics and management of patients with chronic coronary syndrome in the contemporary era, as well as outcomes and their determinants. Data from 32 703 patients (45 countries) with chronic coronary syndrome enrolled in the prospective observational CLARIFY registry (November 2009 to June 2010) with a 5-year follow-up, were analysed. The primary outcome [cardiovascular death or non-fatal myocardial infarction (MI)] 5-year rate was 8.0% [95% confidence interval (CI) 7.7-8.3] overall [male 8.1% (7.8-8.5); female 7.6% (7.0-8.3)]. A cox proportional hazards model showed that the main independent predictors of the primary outcome were prior hospitalization for heart failure, current smoking, atrial fibrillation, living in Central/South America, prior MI, prior stroke, diabetes, current angina, and peripheral artery disease. There was an interaction between angina and prior MI (P = 0.0016); among patients with prior MI, angina was associated with a higher primary event rate [11.8% (95% CI 10.9-12.9) vs. 8.2% (95% CI 7.8-8.7) in patients with no angina, P < 0.001], whereas among patients without prior MI, event rates were similar for patients with [6.3% (95% CI 5.4-7.3)] or without angina [6.4% (95% CI 5.9-7.0)], P > 0.99. Prescription rates of evidence-based secondary prevention therapies were high. This description of the spectrum of chronic coronary syndrome patients shows that, despite high rates of prescription of evidence-based therapies, patients with both angina and prior MI are an easily identifiable high-risk group who may deserve intensive treatment. ISRCTN43070564.

Identifiants

pubmed: 31504434
pii: 5556903
doi: 10.1093/eurheartj/ehz660
pmc: PMC6964227
doi:

Banques de données

ISRCTN
['ISRCTN43070564']

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

347-356

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Circulation. 2017 Nov 14;136(20):1908-1919
pubmed: 28844989
Lancet. 2003 Sep 6;362(9386):782-8
pubmed: 13678872
Eur Heart J. 2012 Aug;33(16):2088-97
pubmed: 22511654
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Coron Artery Dis. 2017 Dec;28(8):636-641
pubmed: 28914638
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Clin Cardiol. 2017 Oct;40(10):797-806
pubmed: 28561986
Lancet. 2001 May 5;357(9266):1385-90
pubmed: 11356434
Lancet. 2009 May 30;373(9678):1849-60
pubmed: 19482214
Am J Cardiol. 1972 Feb;29(2):154-63
pubmed: 5058341
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
JAMA. 2014 Mar 5;311(9):919-28
pubmed: 24595776
Eur Heart J. 2018 Feb 14;39(7):508-579
pubmed: 29190377
Lancet. 2016 Oct 29;388(10056):2142-2152
pubmed: 27590221
J Am Coll Cardiol. 2017 May 2;69(17):2149-2156
pubmed: 28449776
JAMA. 2011 Apr 27;305(16):1677-84
pubmed: 21521849
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Eur Heart J. 2005 May;26(10):996-1010
pubmed: 15778205
JAMA Intern Med. 2014 Oct;174(10):1651-9
pubmed: 25110899
BMJ. 2006 Feb 4;332(7536):262-7
pubmed: 16415069
JAMA. 2012 Sep 12;308(10):998-1006
pubmed: 22928184
Eur Heart J. 2012 Nov;33(22):2831-40
pubmed: 22922505
Circulation. 2014 Nov 4;130(19):1749-67
pubmed: 25070666
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
JAMA. 2010 Sep 22;304(12):1350-7
pubmed: 20805624
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Circulation. 1994 Dec;90(6):2645-57
pubmed: 7994804
JAMA. 2006 Jan 11;295(2):180-9
pubmed: 16403930

Auteurs

Emmanuel Sorbets (E)

Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, 125 rue de Stalingrad, 93000 Bobigny, France.
Paris 13 University, 74 rue Marcel Cachin, 93000 Bobigny, France.
NHLI Imperial College, Dovehouse Street, London SW3 6LP, UK.
ICMS, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, INSERM U1148, Laboratory for Vascular Translational Science, 46 rue Henri Huchard, 75018 Paris, France.

Kim M Fox (KM)

NHLI Imperial College, Dovehouse Street, London SW3 6LP, UK.
ICMS, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.

Yedid Elbez (Y)

Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, INSERM U1148, Laboratory for Vascular Translational Science, 46 rue Henri Huchard, 75018 Paris, France.

Nicolas Danchin (N)

Université de Paris, 15 rue de l'école de médecine, 75005 Paris, France.
Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015 Paris, France.

Paul Dorian (P)

University of Toronto, Department of Medicine, Suite RFE 3-805, 190 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.

Roberto Ferrari (R)

University of Ferrara Via Aldo Moro 8, 44124 Cona (FE) Italy and Maria Cecilia Hospital, GVM Care & Research, Via Corriera, 1 - 48033 Cotignola (RA), Italy.

Ian Ford (I)

Robertson Centre for Biostatistics, Boyd Orr Building, University Avenue, University of Glasgow, Glasgow G12 8QQ, UK.

Nicola Greenlaw (N)

Robertson Centre for Biostatistics, Boyd Orr Building, University Avenue, University of Glasgow, Glasgow G12 8QQ, UK.

Paul R Kalra (PR)

Cardiology department, Queen Alexandra Hospital, Southwick Hill Rd, Portsmouth, UK.

Zofia Parma (Z)

Department of Cardiology and Structural Heart Disease, School of Medicine in Katowice, Medical University of Silesia, Ziolowa Street 45/47, 40-635 Katowice, Poland.

Svetlana Shalnova (S)

National Research Center for Preventive Medicine, Moscow, Bldg. 3, 10, Petroverigskiy Pereulok, 101990, Moscow, Russian Federation.

Jean-Claude Tardif (JC)

Montreal Heart Institute, Université de Montreal, 5000 rue Belanger, Montreal, QC H1T 1C8, Canada.

Michal Tendera (M)

Department of Cardiology and Structural Heart Disease, School of Medicine in Katowice, Medical University of Silesia, Ziolowa Street 45/47, 40-635 Katowice, Poland.

José Luis Zamorano (JL)

University Hospital Ramon y Cajal, Carretera Colmenar Km 9,100, 28034 Madrid, Spain.

Emmanuelle Vidal-Petiot (E)

Université de Paris, 15 rue de l'école de médecine, 75005 Paris, France.
Physiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat and INSERM U1149, Centre de Recherche sur l'Inflammation, 46, rue Henri Huchard, 75018 Paris, France.

Philippe Gabriel Steg (PG)

NHLI Imperial College, Dovehouse Street, London SW3 6LP, UK.
ICMS, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, INSERM U1148, Laboratory for Vascular Translational Science, 46 rue Henri Huchard, 75018 Paris, France.
Université de Paris, 15 rue de l'école de médecine, 75005 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH